The boxed warning, nobody reads; what 20 years of breast implants due to a woman’s body

The Boxed Warning Nobody Reads: What 20 Years of Breast Implants Actually Does to a Woman's Body

Two cancers. A Class I recall. Rupture rates approaching 50 percent. And a suicide signal that doesn't appear until year ten. A psychiatrist examines what the data actually shows — and what women are never told.

A patient I'll call Denise, 52, came to see me for depression and cognitive fog that had been building for years. She had silicone implants placed at 34. Eighteen years in, she was exhausted in a way sleep didn't fix, her joints ached, her memory had become unreliable, and her mood had flattened into something she described as "grey." She had seen a rheumatologist, an endocrinologist, and two primary care physicians. Every workup came back "essentially normal." Nobody had asked about her implants.

I want to say something plainly at the outset, because I think patients deserve directness rather than institutional hedging: a breast implant is a permanent foreign body, placed in tens of thousands of healthy women every year, that the FDA itself now says is not a lifetime device and that carries a boxed warning, the most serious label designation American medicine can attach to a product. That is not a fringe position. That is the regulator's own language. And the full picture of what these devices do over fifteen, twenty, thirty years is considerably darker than the reassuring counseling most women receive before surgery.

Part One: The Regulatory Record Is Damning

Start with what is not in dispute, because the uncontested facts are strong enough on their own.

In July 2019 the FDA requested a worldwide recall of Allergan BIOCELL textured implants and tissue expanders. This was a Class I recall, the agency's most serious category, reserved for products where use may cause serious injury or death. Notably, the recall covered inventory on shelves. It did not require removal from the bodies of the women who already had them.

In October 2021, the FDA went further and required every breast implant manufacturer, Allergan, Mentor (Johnson & Johnson), Sientra, and Ideal Implant, to add a boxed warning. The agency also mandated a patient decision checklist that the implanting surgeon must review and the patient must sign. The FDA's stated reason for this was blunt: women told the agency they were not being adequately informed of the risks before surgery.

The boxed warning informs patients that breast implants are not lifetime devices, that the chance of complications increases the longer the implant is in place, that additional surgery may become necessary, and that implants have been associated with a cancer of the immune system. Think about what that means practically: the regulator has formally acknowledged that every woman who receives an implant at 25 is signing up for an indefinite series of future surgeries, and that the risk profile worsens with time.

Part Two: Two Cancers, Not Zero

For decades, women were told implants do not cause cancer. That claim was narrowly true and broadly misleading. Implants have not been shown to increase primary breast cancer. But they cause cancers of their own, arising from the capsule the body builds around the device.

BIA-ALCL

Breast implant-associated anaplastic large cell lymphoma is a non-Hodgkin lymphoma, a cancer of the immune system, that arises in the scar capsule and fluid surrounding an implant. It did not exist as a recognized entity before implants existed. The FDA formally documented the link in 2011.

The case count has climbed steadily. FDA data has documented well over 1,000 reports of BIA-ALCL globally, and by early 2025 the agency had linked 64 deaths to it, with the caveat that incomplete reporting means the true number may be higher. Roughly 86% of reported cases have involved Allergan implants. The FDA no longer classifies BIA-ALCL as a "rare" condition in the technical sense; it now publishes estimated lifetime risk figures instead, which for textured implants have ranged from approximately 1 in 3,817 to 1 in 30,000 depending on the estimate used.

Here is the part that should concern anyone with long-standing implants: the median time from implant placement to BIA-ALCL diagnosis is approximately nine years, with a documented range extending to 22 years. This is a disease of the second and third decade of implantation. A woman told at 30 that her implants are "safe" is being counseled on a follow-up window shorter than the disease's own latency period.

BIA-SCC

Breast implant-associated squamous cell carcinoma is newer, rarer, and considerably more lethal. The FDA issued a safety communication about it in September 2022. It, too, arises from the implant capsule.

The published case series are small but alarming. In a systematic review of 18 identified cases, the mean age at presentation was 56, and the mean time from augmentation to symptoms was roughly 21 years, with a documented range of 10 to 35 years. Most patients had received implants for cosmetic rather than reconstructive reasons. Estimated mortality was approximately 11% at six months and 24% at twelve months. In a separate early review, extracapsular spread was already present in about 69% of cases at the time of presentation, and of the cases with follow-up data, a substantial fraction were deceased or presumed deceased.

The case reporting trend is upward: four cases in the 1990s, fourteen since 2010. Whether that reflects rising incidence or rising recognition is unknown, and that uncertainty is itself the point. We are twenty-plus years into the exposure window for a generation of implant recipients and only now identifying a second implant-associated malignancy.

Part Three: The Devices Fail, Predictably, and Most Women Never Know

Setting aside cancer and autoimmunity entirely, implants fail as mechanical objects, and the failure curve is unforgiving.

Reported ten-year rupture rates for silicone implants range widely by manufacturer and generation, from roughly 6% to as high as 24%, with independent estimates commonly landing in the 15 to 17% range at the ten-year mark. Rupture risk rises meaningfully after year six. And critically, these rates approximately double by year fifteen, with some estimates reaching 35 to 50% by year twenty for certain implant models. In a real-world ultrasound screening study of women with implants placed since 2000, 14% of women scanned had findings consistent with rupture, and 75% of those who went to surgery had the rupture confirmed.

Most of these ruptures are silent. Cohesive silicone gel does not deflate the way saline does; the breast keeps its shape and the woman feels nothing. This is precisely why the FDA recommends surveillance MRI or ultrasound starting at three to six years after placement and repeating every two to three years thereafter, a recommendation that, in practice, an enormous number of women have never been told about and do not follow. That means a substantial population of women is walking around with ruptured devices they don't know about, for years.

When silicone escapes the capsule, it travels. A published case series documented silicone migration to the arm and forearm, the thoracic cavity, the abdominal wall, the legs, and the back. Median time from augmentation to presentation with distant migration was 10 years, with a range out to 30. Two-thirds of those patients had documented chest trauma beforehand. Migrated silicone forms granulomas, provokes local inflammation, and can lodge in lymph nodes.

Capsular contracture, the body's scar tissue tightening painfully around the device, remains the single most common complication across essentially every long-term study, occurring in something on the order of 15 to 20% of patients in manufacturer core studies and far higher in irradiated reconstruction patients, where clinically significant contracture rates above 20% and implant loss rates around 25% have been reported. Reoperation and explantation are common enough that ten-year cumulative surgical re-intervention risk has been reported in the range of 13% for primary augmentation and over 31% for reconstruction.

Put simply: a meaningful minority of women who get implants will be back in an operating room, and the probability of that climbs every year the device stays in.

Part Four: Breast Implant Illness and the Immunology of a Permanent Foreign Body

Breast implant illness, sometimes called systemic symptoms associated with breast implants, is the patient-named syndrome of fatigue, joint and muscle pain, cognitive dysfunction, hair loss, rashes, dry eyes and mouth, and mood disturbance that women attribute to their devices.

In a 2025 systematic review and meta-analysis pooling over 7,000 implant patients across 48 studies, roughly 49% presented with the BII symptom constellation. Thirty-four percent reported joint or muscle pain, 21% reported cognitive dysfunction such as brain fog or concentration loss, and 24% reported fatigue or malaise. Those are not fringe numbers. Whatever one believes about causation, roughly half of the studied implant population is symptomatic.

The mechanistic case is not implausible. Silicone is not biologically inert. It functions as an adjuvant, a substance that amplifies immune response, which is the entire theoretical foundation of ASIA syndrome (Autoimmune/Inflammatory Syndrome Induced by Adjuvants), described by the immunologist Yehuda Shoenfeld. A 2025 study in Biomaterials examining human periprosthetic tissue found that silicone exposure induced an immunogenic response and autoimmune markers in the tissue surrounding implants, demonstrating that silicone does leak and does reach surrounding tissue even with the capsule intact.

And the single most clinically persuasive observation in this entire literature is the explantation signal. Across multiple studies, a significant proportion of women who have their implants removed report improvement or complete resolution of systemic symptoms. Removing the device improves the illness. In clinical medicine, dechallenge response of that kind is meaningful evidence, and it is very difficult to explain away entirely as expectation effect.

Part Five: What the Psychiatric Mortality Data Shows

This is the section of the literature I find most sobering as a psychiatrist, and it is almost never discussed in pre-operative counseling.

Five large epidemiologic mortality cohorts have now consistently found a two- to three-fold elevated suicide rate among women with cosmetic breast implants compared with the general female population. In a pooled analysis, 135 suicides were observed against 66.9 expected, a standardized mortality ratio of 2.0. In extended follow-up of a Swedish national cohort of 3,527 women followed for over 65,000 person-years, the suicide SMR was 3.0, alongside a comparable three-fold excess in deaths from alcohol or drug dependence. In one American cohort, at least 22% of all deaths were attributable to suicide, psychiatric disorders, or substance dependence.

Two findings within that data deserve particular emphasis. First, elevated risk of death from motor vehicle accidents and substance dependence tracks alongside the suicide excess, which several authors have interpreted as suggesting some of these deaths may not have been fully accidental. Second, and most striking: the excess suicide risk was not apparent until roughly ten years after implantation. The signal emerges in the second decade, precisely the same window in which BIA-ALCL, BIA-SCC, rupture, and BII symptoms all cluster.

Now, intellectual honesty requires stating the standard interpretation: most epidemiologists reading this data conclude it reflects pre-existing psychiatric morbidity in the population that seeks augmentation, body image disturbance, depression, eating disorders, rather than an effect of the device. And there is supporting evidence for that reading, including studies showing women who report BII frequently carried anxiety or depressive diagnoses before implantation.

But notice that this explanation is incomplete on its own terms. If the excess mortality were purely a function of who chooses surgery, you would expect the elevated risk to be present from year one. It isn't. It appears after a decade. Something is happening in that window. It may be the accumulating physical illness. It may be disillusionment when the psychological benefit fades. It may be the burden of complications, reoperations, and being told for years that nothing is wrong. It is very likely some combination. What it clearly is not is "nothing."

And there is a second implication that ought to change practice: if this population carries elevated baseline psychiatric vulnerability, then the appropriate response is rigorous pre-operative psychiatric screening, which is largely not happening. Instead, a group of women at demonstrably higher risk for depression, body dysmorphia, and disordered eating is being routed toward an elective surgical intervention with a two-decade complication tail, often with minimal mental health evaluation.

Part Six: Where the Evidence Is Contested, and Why That Cuts Both Ways

I am not going to tell you the causal case for autoimmune disease is closed, because it isn't, and you would be right not to trust me if I did.

Meta-analyses, notably Janowsky and colleagues, have found no significant association between implants and most connective tissue diseases, with a possible mild signal for Sjögren's. A 2025 study found implant rupture did not produce measurable systemic immune changes. In the 2025 BII meta-analysis, only 6% of patients had a diagnosed comorbid autoimmune condition, and 51% of symptomatic patients had another identifiable diagnosis that explained their symptoms.

But consider the structural problems with that reassuring literature. Much of it relies on self-reported data, short follow-up periods, and small samples. Many studies stop following patients well before the ten-to-twenty-year window in which the serious signals actually appear. A great deal of implant safety research is funded, conducted, or authored within a specialty with obvious financial interest in the answer. And the FDA itself, after decades of these reassurances, still concluded in 2021 that a boxed warning was necessary.

The absence of proof of harm in an under-powered, short-duration, industry-adjacent literature is not proof of absence of harm. That distinction matters enormously when the exposure is permanent, elective, and applied to healthy young women.

And here is what is genuinely missing: after more than sixty years of silicone implants, there is still no large, prospective, independently funded cohort following women for twenty-plus years with rigorous biomarker, imaging, autoimmune, and psychiatric endpoints. That study has not been done. Its absence is not an accident of scientific difficulty.

Part Seven: What This Means Clinically

My clinical position, informed by the above, is this.

The risk profile of breast implants is materially worse than the standard consultation conveys, and virtually all of the serious risk is back-loaded into the second and third decades, which is exactly the period during which most women stop being followed. A woman with implants for 15 or 20 years is in the highest-risk window for rupture, contracture, silicone migration, both implant-associated malignancies, BII symptoms, and the emergent excess psychiatric mortality signal, simultaneously.

Practically, for women who currently have long-standing implants:

• Know your implant manufacturer, model, texture, and placement date. If you have textured Allergan BIOCELL implants, that is specifically relevant information.
• Get imaging. If you have silicone implants and have never had a screening MRI or ultrasound, you are overdue, regardless of how you feel.
• Any new unilateral swelling, seroma, breast enlargement, pain, or mass, particularly years after healing, requires urgent evaluation, not reassurance. That is the presentation of both BIA-ALCL and BIA-SCC.
• If you have unexplained fatigue, joint pain, cognitive fog, or mood change and a negative standard workup, the implants belong in the differential rather than being ruled out by default.
• Explantation is a legitimate medical option to discuss with a plastic surgeon, and the outcome data on symptom improvement after removal is one of the more consistent findings in this field.

And for women considering augmentation: you are being asked to accept a permanent foreign body with a boxed warning, a documented association with two capsule-derived cancers, a device failure curve that steepens with every year, and an unresolved but non-trivial immunological question, in exchange for a cosmetic outcome. That may still be a reasonable trade for a fully informed adult. It is not a reasonable trade for a woman who was told it was "very safe" and left the consultation believing the device would simply sit there for life.

Back to Denise

Denise's imaging showed a silent rupture that had likely been present for years. Nobody had ever ordered surveillance. Her depression was real and needed treating on its own terms, but it had been treated for six years as a purely psychiatric problem in a woman with an undiagnosed ruptured silicone device and a rising inflammatory burden. Both things were true at once, and the medical system had only been willing to see one of them.

That, more than any single statistic in this article, is what I want women to take from it. You are entitled to have the question taken seriously. The data is more than sufficient to justify asking it.

If you are struggling with thoughts of suicide or self-harm, support is available. In the United States, you can call or text 988 to reach the Suicide & Crisis Lifeline, 24 hours a day.

This article is for educational purposes and does not constitute medical advice. Breast implant illness is not a formally established diagnostic entity, and the causal relationship between implants and autoimmune disease remains scientifically contested. Decisions about implants, surveillance, or explantation should be made individually with your physician and a board-certified plastic surgeon.

Keywords: breast implant illness, BIA-ALCL, BIA-SCC, silicone implant rupture, breast implants autoimmune disease, ASIA syndrome, FDA breast implant boxed warning, explantation, silicone migration, capsular contracture, breast implant depression, integrative psychiatry Palm Beach
Hashtags: #BreastImplantIllness #BIAALCL #ExplantAwareness #ASIASyndrome #AutoimmuneHealth #WomensHealth #IntegrativePsychiatry #InformedConsent #PalmBeachPsychiatry